Microbix Biosystems Inc. saw a notable uptick in its stock price this week, reflecting a growing interest among investors.
Microbix Biosystems Inc. (MBX.TO) has experienced positive momentum, with shares rising by 4.92% today and 11.30% over the past week. This surge in stock price comes amidst recent company developments and a focus on its financial performance.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$41.78M
52W high
$0.33
52W low
$0.21
1W change
+11.30%
Beta
0.57
Analyst Price Targets
Based on analyst covering MBX
Wall Street analysts forecast MBX stock price to rise 25.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+25.0% Upside
Current Price
C$0.32
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
46.0%
Annualized
90-Day Vol
50.6%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.38
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.34 | C$0.29 โ C$0.40 |
| 60 trading days | C$0.36 | C$0.29 โ C$0.45 |
| 90 trading days | C$0.38 | C$0.29 โ C$0.50 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: As Microbix continues to report revenue growth and address operational challenges, investors may find its recent stock performance encouraging, although the company still faces hurdles in profitability.
Microbix Reports 17% Revenue Growth in Q3 Fiscal 2026
Despite a controlled net loss, Microbix's Q3 revenues reached $4.1 million, indicating a potential turnaround that investors are closely watching.
Bull case
The recent revenue growth reported in Q3 fiscal 2026 suggests that Microbix is on a path toward recovery and potential profitability. This trend could attract more investors looking for promising opportunities.
Bear case
Despite the positive revenue growth, the company's ongoing net losses and cybersecurity challenges present risks to its long-term stability and could impact investor confidence.
Recent Price Action
Advertisement
Microbix Biosystems Inc. (MBX.TO) has shown a strong upward trend in its stock price. Today's closing price of C$0.32 represents a 4.92% increase, while the stock has gained 11.30% over the past week. Year-to-date, the stock is up 33.33%, reflecting growing interest from investors.
Company Developments
Recent headlines indicate that Microbix reported Q3 fiscal 2026 results on August 13, 2026, revealing revenues of $4.1 million, a 17% increase from the previous year. This revenue growth is a positive sign for the company, although it continues to operate with a controlled net loss. Investors are also keeping an eye on the company's response to previous cybersecurity incidents, which have raised concerns about operational stability.
Technical Picture
From a technical perspective, Microbix is currently trading at C$0.32, which is above its 50-day moving average of C$0.30 (+6.0%) and significantly above its 200-day moving average of C$0.26 (+23.8%). The stock's 52-week range is C$0.21 to C$0.33, indicating it is trading at 92% of its range. With a beta of 0.57, the stock exhibits lower volatility compared to the broader market. However, the volume of 5,000 shares today is notably below the 20-day average volume of 33,910 shares, suggesting a lack of investor interest at current levels.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
